Molecular Partners AG Total Liabilities
Molecular Partners AG total liabilities. Based on the latest financial reports, Molecular Partners AG (MOLN) has total liabilities worth CHF17.15 Million CHF (≈ $21.69 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check MOLN financial resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Molecular Partners AG (2013–2025)
Total liabilities of Molecular Partners AG from 2013 to 2025. This chart illustrates how Molecular Partners AG's total liabilities have evolved over time, based on quarterly financial data.
Molecular Partners AG Competitors by Total Liabilities
The table below lists competitors of Molecular Partners AG ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
The Metals Royalty Company Inc. Common Stock
NASDAQ:TMCR
|
USA | $1.76 Million |
|
Harbour Link Group Bhd
KLSE:2062
|
Malaysia | RM324.48 Million |
|
Amir Marketing and Investments in Agriculture Ltd
TA:AMRK
|
Israel | ILA556.14 Million |
|
Jindal Photo Limited
NSE:JINDALPHOT
|
India | Rs833.80 Million |
|
Arbor Technology
TWO:3594
|
Taiwan | NT$2.37 Billion |
|
Ellington Residential Mortgage
NYSE:EARN
|
USA | $66.83 Million |
|
Oncoclinicas do Brasil
SA:ONCO3
|
Brazil | R$7.02 Billion |
|
Heritage Distilling Holding Company, Inc. Common Stock
NASDAQ:CASK
|
USA | $29.42 Million |
Liability Composition Analysis (2013–2025)
This chart breaks down Molecular Partners AG's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Molecular Partners AG balance sheet assets.
Liquidity & Leverage Metrics
Molecular Partners AG Total Liabilities Ratios Explained
Molecular Partners AG total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.27 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.29 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.23 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Molecular Partners AG's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Molecular Partners AG (2013–2025)
The table below shows the annual total liabilities of Molecular Partners AG from 2013 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CHF21.77 Million ≈ $27.53 Million |
+28.90% |
| 2024-12-31 | CHF16.89 Million ≈ $21.35 Million |
-22.95% |
| 2023-12-31 | CHF21.92 Million ≈ $27.72 Million |
-19.08% |
| 2022-12-31 | CHF27.09 Million ≈ $34.25 Million |
-58.56% |
| 2021-12-31 | CHF65.38 Million ≈ $82.66 Million |
-18.61% |
| 2020-12-31 | CHF80.33 Million ≈ $101.55 Million |
+58.13% |
| 2019-12-31 | CHF50.80 Million ≈ $64.22 Million |
-19.95% |
| 2018-12-31 | CHF63.45 Million ≈ $80.22 Million |
+129.12% |
| 2017-12-31 | CHF27.69 Million ≈ $35.01 Million |
-42.67% |
| 2016-12-31 | CHF48.30 Million ≈ $61.07 Million |
-28.55% |
| 2015-12-31 | CHF67.60 Million ≈ $85.47 Million |
+48.44% |
| 2014-12-31 | CHF45.54 Million ≈ $57.57 Million |
-26.31% |
| 2013-12-31 | CHF61.80 Million ≈ $78.13 Million |
-- |
About Molecular Partners AG
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the trea… Read more